Trametinib-Resistant Melanoma Cells Displaying MITF<sup>high</sup>/NGFR<sup>low</sup>/IL-8<sup>low</sup> Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge

Trametinib-Resistant Melanoma Cells Displaying MITF<sup>high</sup>/NGFR<sup>low</sup>/IL-8<sup>low</sup> Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge

Despite significant advances in targeted therapies against the hyperactivated BRAF<sup>V600</sup>/MEK pathway for patients with unresectable metastatic melanoma, acquired resistance remains an unsolved clinical problem. In this study, we focused on melanoma cells resistant to trametinib,...

Full description

Bibliographic Details
Main Authors: Paulina Koziej, Katarzyna Kluszczynska, Mariusz L. Hartman, Malgorzata Czyz
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:International Journal of Molecular Sciences
Subjects:
cancer cell plasticity
drug holiday
drug rechallenge
IL-8
MITF
melanoma
Online Access:https://www.mdpi.com/1422-0067/24/9/7891

Similar Items

Similar Items